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In December 1997, an epidemic of bloody
diarrhea was reported in Ngoïla, a village of
approximately 500 inhabitants, approximately
400 km from Yaoundé. Canoes and motorbikes
are necessary to reach Ngoïla, which is linked to
Lomié by a difficult road across the Dja River.
The remote zone to the south of the river is
inhabited by 2,610 persons, who belong to two
ethnic groups (Bantus and Baka Pygmies) and
live in 22 villages (Figure 1). The population of
the outbreak area is 20,600. The sanitation
system is weak, latrines do not exist, and human
feces are used as fertilizer. No village has
running water; drinking water, which is neither
chlorinated nor filtered, comes from wells or
small streams.
Between December 1997 and March 1998,
teams from Lomié Hospital and the East
Provincial Delegation of Health went to Ngoïla to
treat patients and make an inventory of the
cases. After a March 19, 1998, wire service report
of a possible viral hemorrhagic fever epidemic in
Ngoïla, a joint mission of Centre Pasteur du
Cameroun and the World Health Organization
visited the area March 25-28, 1998.
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Between November 1997 and April 20, 1998, bloody diarrhea sickened 298
persons in Cameroon. Laboratory investigation of the epidemic (case-fatality rate,
16.4%) documented amoebiasis in one of three patients and three types of pathogens:
multidrug-resistant  Shigella dysenteriae type 1, S. boydii, and enterohemorrhagic
Escherichia coli. We report the first isolation of E. coli O157:H7 in Cameroon and the
second series of cases in the Central African region.
Figure 1. Progression of the bloody diarrhea
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The Investigation
Investigators defined a case as bloody
diarrhea. Data on patients age, sex, village of
origin, onset of disease, drugs received, and
disease diagnosis were obtained from the
observation record book of the Lomié medical
officer. Standardized observation forms were
filled out for 34 patients (from nine villages) seen
during the mission. Serum specimens were
obtained from 21 patients (both current and
former) in three different villages, and stool
specimens were obtained from 22 patients.
Serum specimens were immediately frozen in
liquid nitrogen. Stool specimens were cultured
immediately in a field laboratory set up in each of
the three villages. Later, in the laboratories of
Centre Pasteur in Yaoundé and the Institut
Pasteur of Bangui, the cultures were identified,
their susceptibility to antibiotics was determined
(according to the diffusion method on agar
plates), and genetic studies were conducted.
Hektoen agar plates, purple bromocresol agar
plates, MacConkey Sorbitol medium and
thiosulfate-citrate-bile- saccharose medium
(Sanofi, Marnes la Coquette, France) were used.
Isolates that agglutinated in O157 antise-
rum were confirmed biochemically as Escheri-
chia coli and screened for the lack of enzyme
ß glucuronidase, using the substrate 4-
methylumbelliferyl-ß-D-glucuronide. Specific
anti-O157 and anti-H7 were obtained from Difco,
USA. Toxin production was assayed as follows.
We used the Gb3 enzyme-linked immunosorbent
assay described by Ashkenazi and Cleary (1) for
detection of Verotoxin. Cytotoxicity assays and
seroneutralization tests were performed accord-
ing to procedures (2) with Vero cells. The
antisera to purified Verotoxin and Shiga toxin
had been used in previous studies (3,4) and were
prepared in New Zealand white rabbits to
perform seroneutralization. The Verotoxin 1
preparations we used were purified from E. coli
E40705 (O157:H7) provided by the Public Health
Laboratory Service, London, United Kingdom,
by the procedure described by OBrien and
LaVeck (5). Sera to Shiga toxin from Shigella
dysenteriae type 1 (provided by the Institut
Pasteur, Paris, France) were prepared according
to a  previously described procedure (4).
Virulence genes of E. coli were investigated by
molecular biology techniques; polymerase chain
reaction was used to detect enterohemorrhagic
Shigalike toxins 1 and 2 genes and the attaching
and effacing gene eae (6-8).
Part of each stool specimen was conserved in
a medium containing Merthiolate-formalized
iodine for further parasitologic analyses. Viral
hemorrhagic fever agents were sought by gene
amplification and immunoglobulin M detection.
The Outbreak
The first cases were reported at the end of
November 1997 in two small villages, Dounzok
and Lamson, near Ngoïla. An additional two
cases were found retrospectively, at the end of
November, one each in Djadom and Yanebot,
villages south of Ngoïla. The epidemic began to
affect Ngoïla at the beginning of December 1997
and then, traveling north along the roads, spread
to all villages in the area. It crossed the Dja River
and reached Messok on February 4 and Lomié,
divisional headquarters of the district, on April 3
(Figure 1). By April 20, 298 cases had been
reported from 28 villages.
In the first villages affected, each with fewer
than 100 inhabitants, the epidemic lasted an
average 3 months (57 days to 112 days), with an
attack rate of more than 50%. Villages south of
the Dja had an attack rate of 9.7% (253 of 2,610).
In Ngoïla, the village with the most cases, more
than a fourth of the inhabitants were sick. The
graph of the epidemic for the 271 patients with a
known date of illness onset suggests person-to-
person transmission, with a slow increasing
gradient consisting of successive waves (Figure 2).
Of 10 patients examined at Messok, 7
belonged to the same family (of 12); 2 carried
S. dysenteriae type 1, and 3 carried
enterohemorrhagic  E. coli (EHEC). Disease
onset spread out over 4 weeks, with the index
Figure 2. Cases of bloody diarrhea, by week,
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Table 1. Bloody diarrhea epidemic in  22 villages south of
the Dja River, East Cameroon, 1997–1998
Age Female Male
group  Rate  Rate
(yr) Cases No.a (%) Cases No.a  (%) p
   0-4   16    221   (7.2)   14    218   (6.4)   NSb
   5-9   16    191   (8.4)   11    191   (5.8)   NS
 10-19   25    321   (7.8)   18    313   (5.8)   NS
 20-29   22    211 (10.4)   25    207 (12.1)   NS
 30-39   15    127 (11.8)   14    154   (9.1)   NS
 40-49   16      89 (18.0)   14    101 (13.9)   NS
 50-59   11      63 (17.5)     4      70   (5.7) <0.05
 60  +   25      63 (39.7)     7      69 (10.1) <10-4
Total 146 1,286 (11.4) 107 1,324   (8.1) <0.01
p <10-8 <0.05
aNumber of village inhabitants.
bNS, not significant.
case in week 1, two cases in week 2, one case in
week 3, and three cases in week 4. The median
delay between illness onset was 6 days (range 3
to 8 days). A relative who came to visit family
members in the Messok Health Center was the
last case in this family. He became ill 7 days
later; he had Shigella and Entamoeba infections.
The many Pygmies in the region (who live in
separate villages) were not affected by the
epidemic. Both sexes in all age groups became
sick. The attack rate for the villages south of the
Dja (with known population sizes) was higher
among female (11.4%) than among male
residents (8.1%) (p <0.02) and increased with age
(Table 1). The case-fatality rate was highest for
women ages 60 years and older (39.7%).
Illness, Treatment, and Deaths
The most frequent signs of illness in the 34
investigated patients were abdominal pain (97%)
and mucus in stools (91%), followed by fever
(53%), vomiting (50%), and dehydration (41%).
The average number of stools per day was 10;
mucus and blood were observed in stools starting
on the third day. The quantity of blood in the
stools varied; occasionally only blood was
excreted.
Stool specimens were obtained from 12
female and 10 male patients; their median age
was 25 (2 years to 60 years), and the median
length of illness was 7 days (3 days to 58 days).
African hemorrhagic fever was not detected.
Parasitologic examination of stool specimens
showed heavy infestation with numerous
parasites. Hematophagous trophozoites of Enta-
moeba histolytica histolytica were observed in 7
(31.8%) of 22 of the cases. Bacteriologic studies
isolated at least 1 enteropathogen in 20 (90.9%).
EHEC were isolated in 12 (54.5%), S. dysenteriae
type 1 in 9 (40.9%), and S. boydii in 2 (9.1%).
Potentially dangerous associations were com-
mon. Of the 22 patients with stool specimens, 7
(31.8%) had both E. histolytica histolytica and
one enteropathogenic bacterium; 3 (13.6%) had
both E. histolytica histolytica and S. dysenteriae
type 1; and 2 (9.1%) had both S. dysenteriae type
1 and EHEC. Simultaneous infection with all
three pathogensS. dysenteriae, EHEC, and
E. histolyticawere found in patients from all
three villages, while dual infections with
S. dysenteriae and EHEC were observed in
patients from two villages.
Drug susceptibility testing found that
S. dysenteriae type 1 was resistant to
amoxicillin, amoxicillin in combination with
clavulanic acid, tetracycline, chloramphenicol,
cefsulodin, and cotrimoxazole; it was sensitive to
nalidixic acid, piperacillin, cefalotin, ceftazidin,
gentamicin, and ofloxacin. E. coli O157:H7 was
resistant to amoxicillin, chloramphenicol, and
cefsulodine, and sensitive to amoxicillin in
combination with clavulanic acid, tetracycline,
cotrimoxazole, nalidixic acid, and cefalotin. DNA
amplification showed that E. coli O157:H7
strains had genes that coded for Shigalike toxins
1 and 2 and the attaching and effacing gene eaeA.
By April 1998, five different medications,
depending on availability, had been used,
sometimes in combination. Of the 292 patients
with known drug regimens, 182 took
cotrimoxazole (62.3%), 190 took metronidazole
(65.1%), 34 took chloramphenicol (11.6%), and 19
took tetracycline (6.5%). Of these, 67 (22.9%)
were given oral rehydration salts, while 71
(24.3%) received no treatment or received
traditional medicine. More female than male
patients were not treated, 51 (31.1%) of 164
versus 20 (15.6%) of 128 (p <0.01), respectively.
The groups that received the least or no drug
treatment were children younger than 5 years of
age (12 [34.3%] of 35) and those ages 50 years and
older (26 [46.4%] of 56). The proportion of
patients treated with drugs increased during the
epidemic: 24 (54.5%) of 44 of the patients were
treated in December 1997, while 41 (68.3%) of 60,
85 (76.6%) of 111, and 44 (88%) of 50 were treated
in January, February, and March, 1998, respectively.
Of the 275 patients for whom disease
outcome was known, 45 died (case-fatality rate288 Emerging Infectious Diseases Vol. 5, No. 2, MarchApril 1999
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Table 2. Bloody diarrhea epidemic in East Cameroon,
case-fatality rate of  by age and sex
Age
group Female Male
(yr) Cases Deaths  (%) Cases Deaths (%)  p
   0-4   18   5 (27.8)   16   3   (18.8)   NSa
   5-9   16   2 (12.5)   13   1     (7.7)   NS
 10-19   25   1   (4.0)   20   1     (5.0)   NS
 20-29   24   1   (4.2)   27   1     (3.7)   NS
 30-39   16   3 (18.8)   18   1     (5.6)   NS
 40-49   17   3 (17.6)   12   1     (8.3)   NS
 50-59   13   6 (46.2)     8   2   (25.0)   NS
 60  +   26 12 (46.2)     6   2   (33.3)   NS
Total 155 33 (21.3) 120 12   (10.0) <0.02
aNS, not significant.
16.4%). The rate was higher in female (21.3% [33
of 155]) than in male patients, (10% [12 of 120]) (p
<0.02) (Table 2). Case-fatality rates were 23.5%
(8 of 34) among those younger than 5 years old,
40% (22 of 55) among those 50 years of age and
older, and 53.5% (38 of 71) among patients who
received no treatment.
Conclusions
During the first half of 1997, an epidemic of
bloody diarrhea with a case-fatality rate of 19%
was reported in villages near Mintom, a district
headquarters approximately 100 km west of
Ngoïla. Then, the region of Ngoïla in the East
Province of Cameroon was hit by an extremely
severe and deadly epidemic of bloody diarrhea,
which continued until July 1998. In April 1998,
34 (11.4%) of 298 (the affected population) were
examined, and stool specimens were obtained
from 22 patients with an active infection, which
represented 7.4% of the total epidemic popula-
tion (298). Although the sample was relatively
small, three bacterial enteropathogens
(S. dysenteriae type 1, S. boydii, and EHEC)
associated with numerous parasites were
isolated from the stool specimens. Thus, which of
these pathogens were responsible for the
epidemic and its severity is not known with
certainty. The isolation of E. coli O157, in
contrast to Shigella, is quite recent in Africa. We
believe that this is the first case of E. coli O157
described in Cameroon and the second (after the
1996 epidemic in the Republic of Central Africa)
in the Central African region (9).
A few persons may have contracted the
disease through food or drink. However, the
epidemic curve with a slow rise of successive
waves does not depict a common source of
contamination; it suggests person-to-person
transmission. The spread of the disease followed
roads, and women were the most likely infected,
probably because they live together in groups
and take care of the sick. Because of difficulties
in communication and the necessity to return to
the laboratory to process the specimens, we could
not investigate in detail with a case-control
study. The protracted course of the illness, poor
sanitation, and length of time patients were
infected with pathogens favored transmission.
The bloody diarrhea was long-lasting for some
patients. In one patient with S. dysenteriae type
I, the onset of disease had begun 58 days before,
while in another with EHEC, it had begun 39
days before.
In contrast to shigellosis, which is most often
transmitted from person to person (10) (often
through the hands) (11) and affects mostly
women (12), E. coli O157 infection has been
described in the northern hemisphere as food
poisoning (13). For example, in Japan an
epidemic involving more than 5,000 cases was
described in school children contaminated by
food prepared in the school canteen in 1996 (14).
Sources of contamination most commonly
incriminated are meat in hamburgers (15) or
sandwiches (16), milk (17), drinking water (18),
water absorbed during baths (19), nonpasteurized
apple juice (20), and salads (21). The main
reservoir of the germ is cows and other
ruminants (22), but the association between
E. coli O157 and cows is not absolute (23). Its
transmission from person to person has been
observed in a small number of cases, most often
intrafamilially (24). In the Republic of Central
Africa during the first isolation of E. coli O157,
food was the suspected vehicle (9). The rain
forest zone in South and East Cameroon, like
Ngoïla, has no cattle; breeding is limited to pigs,
goats, and chickens; and meat is not imported.
Deaths caused by the disease were quite
high, with a case-fatality rate of 16.4%. In
comparison, the case-fatality rate for cholera was
globally estimated at 4.7% in 1996 (25) and rose
to 48% in the worst outbreak (the beginning of
the epidemic in Rwanda refugee camps in Goma
in 1994) (26). Shigellosis is one of the main causes
of severe diarrhea in Africa, accounting for 12%
of all deaths in Kibue Sector in Burundi in 1992
(12) and 19% of pediatric hospital deaths in
KwaZulu-Natal in 1995 (27). The portion of289 Vol. 5, No. 2, MarchApril 1999 Emerging Infectious Diseases
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deaths due to shigellosis variesfrom 13% in
hospital statistics in children in KwaZulu-Natal
to 3.8% in a Burundan refugee camp in Rwanda
in 1993 (28) and 0.25% during the first Shigella
epidemic in Mozambique in the same year (29).
The severity of E. coli O157 is associated with its
complication, hemolytic uremic syndrome; an
estimated 200,000 cases of this syndrome per
year occur in the United States, with 250 deaths
and a case-fatality rate of 0.1% (30). In the
epidemic in the Republic of Central Africa, the
case-fatality rate was 3.7% (9).
The causes of death were unknown. The
case-fatality rate diminished during the course
of the epidemic: 14 (31.8%) of 44 in patients in
December 1997, 9 (15%) of 60 in January, 19
(18.3%) of 104 in February, and 2 (5%) of 40 in
March 1998 (p <0.02), suggesting progressively
better disease management during the epidemic.
The case-fatality rate was 3.4% in patients who
received either cotrimoxazole (6/174), metron-
idazole (6/176), or chloramphenicol (1/29); 5.5%
in those who were given tetracycline (1/18); 0% in
patients who also received oral rehydration salts;
and 53.5% (38/71) in those who received no
treatment. In Ngoïla, health facilities did not
have the resources to perform the classic
hematologic and chemical investigations. How-
ever, the case-fatality rate in patients who
received oral rehydration salts was zero,
suggesting that fluid loss was a major part of the
disease. Other cofactors (e.g., anemia) could
have played a role in lethality. To determine the
risk for death from the disease, we constructed a
logistic regression model that included age, sex,
onset of illness, and drug regimen received. Oral
rehydration salts were not included in the model
(all rehydrated patients survived). The only
factor strongly associated with death was age
>50 years (odds ratio [OR] = 5 ; 95% confidence
interval [CI]: 2.2-11.5); having received
cotrimoxazole was a protective factor (OR = 0.05,
95% CI: 0.02 - 0.13, p <10-5). Because the
treatment groups were not randomized, the
decline in case-fatality rates cannot be attributed
to this drug. The use of other drugs, however, as
well as sex and month of onset of the illness, were
not associated with death. S. dysenteriae type 1
was resistant to cotrimoxazole, while E. coli
O157 was susceptible.
The multiple resistance to antibiotics of
S. dysenteriae type 1 strains isolated from Ngoïla
could also explain the high case-fatality rate.
Studies from Central and East Africa confirm
that  S. dysenteriae type 1 is resistant to multiple
drugs (31-34). There may, therefore, be a new
emerging disease due to the association of
enterohemorrhagic  E. coli O157:H7 and
S. dysenteriae type 1 in this region of Africa, an
association that could be as deadly as that of
shigellosis and cholera. Finally, the manage-
ment of cases will be rendered difficult by the
resistance  of the pathogens implicated to
multiple drugs. After our microbiologic investi-
gations, the health authorities distributed
nalidixic tablets and ciprofloxacin. The case-
fatality rate fell to 3.7% (8/213).
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